Narcolepsy Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report covers the 7 major markets and provides an Excel-based forecast model for the narcolepsy market through 2035
The narcolepsy therapeutics market totaled $4.6 billion in 2025 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan).
It is projected to grow rapidly at 5.5% compound annual growth rate (CAGR) to $7.8 billion by 2035, mainly driven by the entry of orexin agonists from the late-stage pipeline, the introduction of new formulations, and increased treatment rates.
The US has the largest narcolepsy market, accounting for approximately 97% of 7MM sales in 2025 and 2035, due to higher drug prices, the large diagnosed prevalent cases of narcolepsy, and the most products launches during the forecast period.
Scope
Overview of narcolepsy, including epidemiology, symptoms, diagnosis, and disease management.
Annualized narcolepsy market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2025 to 2035.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the narcolepsy therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for narcolepsy treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global narcolepsy market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 7MM narcolepsy therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM narcolepsy therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Axsome Therapeutics
Bioprojet
Bioron Pharma
Centessa Pharmaceuticals
Eli Lilly
Harmony Biosciences
Jazz Pharmaceuticals
SK Biopharmaceuticals
Suven Life Sciences
Synchronicity Pharma
Takeda Pharmaceuticals
Teva Pharmaceuticals
Tris Pharma
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Narcolepsy reports
